Use of allogeneic serum eye drops: Does indication influence patient satisfaction?—Identifying the most satisfied patient cohort and usability of eye-dropper vial

Abstract Background Recent studies have assessed quality-of-life improvements associated with serum eye drops, but existing data lack insight into indication-specific patient satisfaction. This survey aims to identify which patients benefit the most from serum eye drops, determine the cohort with the highest satisfaction, and understand their treatment experience. Subjects/Methods We conducted a patient satisfaction survey incorporating a combination of validated PROMs along with additional questions regarding the use of SED and the quality of service. Patients with severe ocular surface disease (OSD) who received allogeneic serum eye drops at Manchester Royal Eye Hospital, United Kingdom, from 2020 to 2023 were identified from NHSBT clinical requests. Responses were collected between October 2023 and February 2024. Demographic details were collected, and associations between indications and patient satisfaction were analysed. Results Thirty-three patients (21–86 years old) returned the survey questionnaire. The majority were female (55%) and Caucasian (91%). The most common indication was ocular graft versus host disease (GvHD) (21%). The data analysed resulted in three primary themes: ‘quality of life’, ‘patient contentment with treatment for specified indications’ and ‘usability of treatment and eye-dropper vial’. The mean pre-and post-treatment OSDI score was 61 and 48 ( p = 0.035, 95% CI). Conclusions Our data support the use of SED in patients with chronic and debilitating OSD, in particular those with immune-related dry eye disease and persistent epithelial defects. Overall, patient responses were very positive. 55% of patients felt vials were too large and raised concerns around environmental issues.